Literature DB >> 27550356

In Vitro Bactericidal Activity of Trimethoprim-Sulfamethoxazole Alone and in Combination with Colistin against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates.

Martha Nepka1, Efstathia Perivolioti1, Eleni Kraniotaki1, Lida Politi2, Athanasios Tsakris2, Spyros Pournaras3.   

Abstract

Trimethoprim-sulfamethoxazole alone and combined with colistin was tested in vitro against six carbapenem-resistant Acinetobacter baumannii (CRAB) clinical strains. After 24 h, at achievable serum concentrations, trimethoprim-sulfamethoxazole effectively killed all strains, while colistin killed only one strain. Trimethoprim-sulfamethoxazole plus colistin rapidly killed all strains after 6 h and for up to 24 h. Trimethoprim-sulfamethoxazole, one of the few remaining antimicrobials that still has a degree of activity, particularly combined with colistin, might represent an effective therapy for severe CRAB infections.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27550356      PMCID： PMC5075104          DOI： 10.1128/AAC.01082-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Cerebrospinal fluid concentrations of trimethoprim during oral and parenteral treatment.

Authors:  A Svedhem; S Iwarson
Journal:  J Antimicrob Chemother       Date:  1979-11       Impact factor: 5.790

2.  Comparative in vitro activity of sulfametrole/trimethoprim and sulfamethoxazole/trimethoprim and other agents against multiresistant Gram-negative bacteria.

Authors:  David M Livermore; Shazad Mushtaq; Marina Warner; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2013-11-19       Impact factor: 5.790

Review 3.  Trimethoprim/sulfamethoxazole for Acinetobacter spp.: A review of current microbiological and clinical evidence.

Authors:  Matthew E Falagas; Konstantinos Z Vardakas; Nikolaos S Roussos
Journal:  Int J Antimicrob Agents       Date:  2015-05-15       Impact factor: 5.283

4.  In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates.

Authors:  Céline Vidaillac; Lothaire Benichou; Raphaël E Duval
Journal:  Antimicrob Agents Chemother       Date:  2012-07-02       Impact factor: 5.191

5.  Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions.

Authors:  R Gleckman; N M Gantz; D W Joubert
Journal:  Pharmacotherapy       Date:  1981 Nov-Dec       Impact factor: 4.705

6.  Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria.

Authors:  D Plachouras; M Karvanen; L E Friberg; E Papadomichelakis; A Antoniadou; I Tsangaris; I Karaiskos; G Poulakou; F Kontopidou; A Armaganidis; O Cars; H Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2009-05-11       Impact factor: 5.191

7.  Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.

Authors:  María E Pachón-Ibáñez; Fernando Docobo-Pérez; Rafael López-Rojas; Juan Domínguez-Herrera; Manuel E Jiménez-Mejias; Andrés García-Curiel; Cristina Pichardo; Luis Jiménez; Jerónimo Pachón
Journal:  Antimicrob Agents Chemother       Date:  2010-01-04       Impact factor: 5.191

8.  Single-locus-sequence-based typing of blaOXA-51-like genes for rapid assignment of Acinetobacter baumannii clinical isolates to international clonal lineages.

Authors:  Spyros Pournaras; Vasiliki Gogou; Maria Giannouli; Evangelia Dimitroulia; Konstantina Dafopoulou; Athanasios Tsakris; Raffaele Zarrilli
Journal:  J Clin Microbiol       Date:  2014-03-12       Impact factor: 5.948

Review 9.  Co-trimoxazole (trimethoprim-sulfamethoxazole): an updated review of its antibacterial activity and clinical efficacy.

Authors:  G P Wormser; G T Keusch; R C Heel
Journal:  Drugs       Date:  1982-12       Impact factor: 9.546

Review 10.  Colistin for lung infection: an update.

Authors:  Mohan Gurjar
Journal:  J Intensive Care       Date:  2015-01-22
View more
  9 in total

Review 1.  Antibiotic resistance of pathogenic Acinetobacter species and emerging combination therapy.

Authors:  Bora Shin; Woojun Park
Journal:  J Microbiol       Date:  2017-10-27       Impact factor: 3.422

Review 2.  Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options.

Authors:  Chang-Ro Lee; Jung Hun Lee; Moonhee Park; Kwang Seung Park; Il Kwon Bae; Young Bae Kim; Chang-Jun Cha; Byeong Chul Jeong; Sang Hee Lee
Journal:  Front Cell Infect Microbiol       Date:  2017-03-13       Impact factor: 5.293

Review 3.  Acinetobacter baumannii Resistance: A Real Challenge for Clinicians.

Authors:  Rosalino Vázquez-López; Sandra Georgina Solano-Gálvez; Juan José Juárez Vignon-Whaley; Jorge Andrés Abello Vaamonde; Luis Andrés Padró Alonzo; Andrés Rivera Reséndiz; Mauricio Muleiro Álvarez; Eunice Nabil Vega López; Giorgio Franyuti-Kelly; Diego Abelardo Álvarez-Hernández; Valentina Moncaleano Guzmán; Jorge Ernesto Juárez Bañuelos; José Marcos Felix; Juan Antonio González Barrios; Tomás Barrientos Fortes
Journal:  Antibiotics (Basel)       Date:  2020-04-23

Review 4.  Insight into Acinetobacter baumannii: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities.

Authors:  Muhammad Asif; Iqbal Ahmad Alvi; Shafiq Ur Rehman
Journal:  Infect Drug Resist       Date:  2018-08-21       Impact factor: 4.003

5.  Rapid Nanopore Assay for Carbapenem-Resistant Klebsiella pneumoniae.

Authors:  Haofu Niu; Weili Zhang; Liangwan Wei; Meng Liu; Hao Liu; Changjian Zhao; Peng Zhang; Quanfeng Liao; Ya Liu; Qingyue Yuan; Siying Wu; Mei Kang; Jia Geng
Journal:  Front Microbiol       Date:  2019-07-30       Impact factor: 5.640

6.  Antimicrobial susceptibility pattern of carbapenemase-producing Gram-negative nosocomial bacteria at Al Zahra hospital, Isfahan, Iran.

Authors:  Sima Bahrami; Fatemeh Shafiee; Atousa Hakamifard; Hossein Fazeli; Rasool Soltani
Journal:  Iran J Microbiol       Date:  2021-02

7.  Carbapenemase Genes and Multidrug Resistance of Acinetobacter Baumannii: A Cross Sectional Study of Patients with Pneumonia in Southern Vietnam.

Authors:  Cuong Hoang Quoc; Thao Nguyen Thi Phuong; Hai Nguyen Duc; Trung Tran Le; Hang Tran Thi Thu; Si Nguyen Tuan; Lan Phan Trong
Journal:  Antibiotics (Basel)       Date:  2019-09-12

Review 8.  Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems.

Authors:  Stamatis Karakonstantis; Evangelos I Kritsotakis; Achilleas Gikas
Journal:  Infection       Date:  2020-09-01       Impact factor: 3.553

Review 9.  Acinetobacter baumannii Antibiotic Resistance Mechanisms.

Authors:  Ioannis Kyriakidis; Eleni Vasileiou; Zoi Dorothea Pana; Athanasios Tragiannidis
Journal:  Pathogens       Date:  2021-03-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.